A retrospective study analysing persistence with biologic treatment in patients with Inflammatory Bowel Disease
Latest Information Update: 01 Sep 2021
Price :
$35 *
At a glance
- Drugs Adalimumab (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Vedolizumab (Primary) ; Tumour necrosis factor alpha inhibitors
- Indications Inflammatory bowel diseases
- Focus Therapeutic Use
- 01 Sep 2021 New trial record